nodes	percent_of_prediction	percent_of_DWPC	metapath
Nateglinide—ORM1—Vismodegib—skin cancer	0.181	0.219	CbGbCtD
Nateglinide—ORM1—Vemurafenib—skin cancer	0.143	0.173	CbGbCtD
Nateglinide—ALB—Vismodegib—skin cancer	0.0764	0.0923	CbGbCtD
Nateglinide—ABCC4—Fluorouracil—skin cancer	0.0732	0.0885	CbGbCtD
Nateglinide—ALB—Vemurafenib—skin cancer	0.0604	0.073	CbGbCtD
Nateglinide—CYP2C9—Vismodegib—skin cancer	0.0412	0.0498	CbGbCtD
Nateglinide—CYP3A4—Temozolomide—skin cancer	0.0345	0.0418	CbGbCtD
Nateglinide—CYP3A4—Imiquimod—skin cancer	0.0345	0.0418	CbGbCtD
Nateglinide—CYP2D6—Vemurafenib—skin cancer	0.0298	0.036	CbGbCtD
Nateglinide—ALB—Fluorouracil—skin cancer	0.0271	0.0328	CbGbCtD
Nateglinide—CYP3A4—Vismodegib—skin cancer	0.0239	0.0289	CbGbCtD
Nateglinide—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0222	0.0268	CbGbCtD
Nateglinide—CYP3A7—Docetaxel—skin cancer	0.0222	0.0268	CbGbCtD
Nateglinide—CYP3A4—Vemurafenib—skin cancer	0.0189	0.0229	CbGbCtD
Nateglinide—CYP3A5—Docetaxel—skin cancer	0.0166	0.0201	CbGbCtD
Nateglinide—CYP2C9—Fluorouracil—skin cancer	0.0146	0.0177	CbGbCtD
Nateglinide—ABCC8—penis—skin cancer	0.00711	0.109	CbGeAlD
Nateglinide—PPARG—dermis—skin cancer	0.00695	0.107	CbGeAlD
Nateglinide—CYP3A4—Docetaxel—skin cancer	0.00649	0.00785	CbGbCtD
Nateglinide—PPARG—leg—skin cancer	0.00459	0.0705	CbGeAlD
Nateglinide—PPARG—forelimb—skin cancer	0.00455	0.07	CbGeAlD
Nateglinide—Hepatic enzyme increased—Vismodegib—skin cancer	0.00447	0.0417	CcSEcCtD
Nateglinide—PPARG—hindlimb—skin cancer	0.0041	0.0629	CbGeAlD
Nateglinide—PPARG—appendage—skin cancer	0.00351	0.054	CbGeAlD
Nateglinide—Trauma—Bleomycin—skin cancer	0.00332	0.031	CcSEcCtD
Nateglinide—Hepatic enzyme increased—Imiquimod—skin cancer	0.00235	0.022	CcSEcCtD
Nateglinide—PPARG—endothelium—skin cancer	0.00212	0.0326	CbGeAlD
Nateglinide—Gastrointestinal symptom NOS—Fluorouracil—skin cancer	0.00209	0.0195	CcSEcCtD
Nateglinide—PPARG—blood vessel—skin cancer	0.00196	0.0301	CbGeAlD
Nateglinide—Malnutrition—Vismodegib—skin cancer	0.00185	0.0173	CcSEcCtD
Nateglinide—Back pain—Vismodegib—skin cancer	0.00179	0.0167	CcSEcCtD
Nateglinide—Injury—Imiquimod—skin cancer	0.00176	0.0164	CcSEcCtD
Nateglinide—Neuropathy peripheral—Vemurafenib—skin cancer	0.00143	0.0134	CcSEcCtD
Nateglinide—PPARG—nipple—skin cancer	0.00141	0.0217	CbGeAlD
Nateglinide—Hepatic enzyme increased—Temozolomide—skin cancer	0.00141	0.0132	CcSEcCtD
Nateglinide—PPARG—neck—skin cancer	0.0014	0.0215	CbGeAlD
Nateglinide—Influenza—Imiquimod—skin cancer	0.0014	0.0131	CcSEcCtD
Nateglinide—Sweating increased—Imiquimod—skin cancer	0.00136	0.0127	CcSEcCtD
Nateglinide—Bronchitis—Imiquimod—skin cancer	0.00134	0.0126	CcSEcCtD
Nateglinide—Dyspepsia—Vismodegib—skin cancer	0.00133	0.0124	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Vismodegib—skin cancer	0.0013	0.0122	CcSEcCtD
Nateglinide—Fatigue—Vismodegib—skin cancer	0.0013	0.0121	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Imiquimod—skin cancer	0.0013	0.0121	CcSEcCtD
Nateglinide—Oedema peripheral—Vemurafenib—skin cancer	0.00129	0.0121	CcSEcCtD
Nateglinide—Injury—Bleomycin—skin cancer	0.00125	0.0117	CcSEcCtD
Nateglinide—Erythema multiforme—Vemurafenib—skin cancer	0.00124	0.0116	CcSEcCtD
Nateglinide—Gastrointestinal pain—Vismodegib—skin cancer	0.00123	0.0115	CcSEcCtD
Nateglinide—Neuropathy peripheral—Imiquimod—skin cancer	0.00122	0.0114	CcSEcCtD
Nateglinide—SLC15A1—epithelium—skin cancer	0.00119	0.0183	CbGeAlD
Nateglinide—Abdominal pain—Vismodegib—skin cancer	0.00119	0.0111	CcSEcCtD
Nateglinide—Hepatobiliary disease—Imiquimod—skin cancer	0.00118	0.011	CcSEcCtD
Nateglinide—Malnutrition—Vemurafenib—skin cancer	0.00114	0.0107	CcSEcCtD
Nateglinide—SLC16A1—epithelium—skin cancer	0.00113	0.0174	CbGeAlD
Nateglinide—PTGS1—endothelium—skin cancer	0.00113	0.0174	CbGeAlD
Nateglinide—Back pain—Vemurafenib—skin cancer	0.0011	0.0103	CcSEcCtD
Nateglinide—Asthenia—Vismodegib—skin cancer	0.00108	0.0101	CcSEcCtD
Nateglinide—Pruritus—Vismodegib—skin cancer	0.00107	0.00997	CcSEcCtD
Nateglinide—Erythema multiforme—Imiquimod—skin cancer	0.00106	0.00988	CcSEcCtD
Nateglinide—PTGS1—blood vessel—skin cancer	0.00105	0.0161	CbGeAlD
Nateglinide—KCNJ11—lymphoid tissue—skin cancer	0.00104	0.016	CbGeAlD
Nateglinide—SLC15A1—mammalian vulva—skin cancer	0.00103	0.0159	CbGeAlD
Nateglinide—Diarrhoea—Vismodegib—skin cancer	0.00103	0.00964	CcSEcCtD
Nateglinide—Thirst—Temozolomide—skin cancer	0.00102	0.00951	CcSEcCtD
Nateglinide—Lacosamide—SCN10A—skin cancer	0.00101	1	CrCbGaD
Nateglinide—Immune system disorder—Imiquimod—skin cancer	0.00101	0.00944	CcSEcCtD
Nateglinide—KCNJ11—female reproductive system—skin cancer	0.00101	0.0155	CbGeAlD
Nateglinide—PPARG—connective tissue—skin cancer	0.001	0.0154	CbGeAlD
Nateglinide—Cough—Vemurafenib—skin cancer	0.000996	0.00931	CcSEcCtD
Nateglinide—Malnutrition—Imiquimod—skin cancer	0.000973	0.00909	CcSEcCtD
Nateglinide—Vomiting—Vismodegib—skin cancer	0.000958	0.00896	CcSEcCtD
Nateglinide—PPARG—epithelium—skin cancer	0.000952	0.0146	CbGeAlD
Nateglinide—Rash—Vismodegib—skin cancer	0.00095	0.00888	CcSEcCtD
Nateglinide—Dermatitis—Vismodegib—skin cancer	0.000949	0.00887	CcSEcCtD
Nateglinide—Back pain—Imiquimod—skin cancer	0.000941	0.0088	CcSEcCtD
Nateglinide—PPARG—skin of body—skin cancer	0.000905	0.0139	CbGeAlD
Nateglinide—Nausea—Vismodegib—skin cancer	0.000895	0.00837	CcSEcCtD
Nateglinide—Osteoarthritis—Fluorouracil—skin cancer	0.000892	0.00834	CcSEcCtD
Nateglinide—Palpitations—Imiquimod—skin cancer	0.00086	0.00804	CcSEcCtD
Nateglinide—Cough—Imiquimod—skin cancer	0.000849	0.00794	CcSEcCtD
Nateglinide—SLC16A1—female reproductive system—skin cancer	0.000843	0.013	CbGeAlD
Nateglinide—KCNJ11—head—skin cancer	0.00084	0.0129	CbGeAlD
Nateglinide—PPARG—mammalian vulva—skin cancer	0.000826	0.0127	CbGeAlD
Nateglinide—Sweating increased—Temozolomide—skin cancer	0.000815	0.00762	CcSEcCtD
Nateglinide—Bronchitis—Temozolomide—skin cancer	0.000805	0.00752	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000804	0.00751	CcSEcCtD
Nateglinide—Fatigue—Vemurafenib—skin cancer	0.000803	0.0075	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Temozolomide—skin cancer	0.000778	0.00727	CcSEcCtD
Nateglinide—ABCC8—head—skin cancer	0.000774	0.0119	CbGeAlD
Nateglinide—Hyperhidrosis—Imiquimod—skin cancer	0.000768	0.00718	CcSEcCtD
Nateglinide—ORM1—female reproductive system—skin cancer	0.000756	0.0116	CbGeAlD
Nateglinide—PTGS1—nipple—skin cancer	0.000756	0.0116	CbGeAlD
Nateglinide—PPARG—lymphoid tissue—skin cancer	0.000733	0.0113	CbGeAlD
Nateglinide—Neuropathy peripheral—Temozolomide—skin cancer	0.000731	0.00684	CcSEcCtD
Nateglinide—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000717	0.0067	CcSEcCtD
Nateglinide—PPARG—female reproductive system—skin cancer	0.000707	0.0109	CbGeAlD
Nateglinide—Hepatobiliary disease—Temozolomide—skin cancer	0.000706	0.0066	CcSEcCtD
Nateglinide—SLC16A1—head—skin cancer	0.000704	0.0108	CbGeAlD
Nateglinide—Erythema multiforme—Dactinomycin—skin cancer	0.0007	0.00654	CcSEcCtD
Nateglinide—Dyspepsia—Imiquimod—skin cancer	0.000699	0.00653	CcSEcCtD
Nateglinide—Hypersensitivity—Vemurafenib—skin cancer	0.000686	0.00641	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000686	0.00641	CcSEcCtD
Nateglinide—Fatigue—Imiquimod—skin cancer	0.000685	0.0064	CcSEcCtD
Nateglinide—Neuropathy peripheral—Fluorouracil—skin cancer	0.000674	0.0063	CcSEcCtD
Nateglinide—Asthenia—Vemurafenib—skin cancer	0.000668	0.00624	CcSEcCtD
Nateglinide—Oedema peripheral—Temozolomide—skin cancer	0.00066	0.00617	CcSEcCtD
Nateglinide—Pruritus—Vemurafenib—skin cancer	0.000659	0.00616	CcSEcCtD
Nateglinide—Gastrointestinal pain—Imiquimod—skin cancer	0.000649	0.00607	CcSEcCtD
Nateglinide—ABCC4—female reproductive system—skin cancer	0.000642	0.00987	CbGeAlD
Nateglinide—Diarrhoea—Vemurafenib—skin cancer	0.000637	0.00596	CcSEcCtD
Nateglinide—Erythema multiforme—Temozolomide—skin cancer	0.000633	0.00592	CcSEcCtD
Nateglinide—Urticaria—Imiquimod—skin cancer	0.000631	0.0059	CcSEcCtD
Nateglinide—Abdominal pain—Imiquimod—skin cancer	0.000628	0.00587	CcSEcCtD
Nateglinide—Dizziness—Vemurafenib—skin cancer	0.000616	0.00576	CcSEcCtD
Nateglinide—Immune system disorder—Temozolomide—skin cancer	0.000605	0.00566	CcSEcCtD
Nateglinide—Cough—Bleomycin—skin cancer	0.000603	0.00564	CcSEcCtD
Nateglinide—Vomiting—Vemurafenib—skin cancer	0.000592	0.00553	CcSEcCtD
Nateglinide—PPARG—head—skin cancer	0.000591	0.00908	CbGeAlD
Nateglinide—KCNJ11—lymph node—skin cancer	0.000588	0.00904	CbGeAlD
Nateglinide—Rash—Vemurafenib—skin cancer	0.000587	0.00549	CcSEcCtD
Nateglinide—Dermatitis—Vemurafenib—skin cancer	0.000587	0.00548	CcSEcCtD
Nateglinide—Hypersensitivity—Imiquimod—skin cancer	0.000585	0.00547	CcSEcCtD
Nateglinide—Malnutrition—Temozolomide—skin cancer	0.000583	0.00545	CcSEcCtD
Nateglinide—Asthenia—Imiquimod—skin cancer	0.00057	0.00533	CcSEcCtD
Nateglinide—Back pain—Temozolomide—skin cancer	0.000564	0.00527	CcSEcCtD
Nateglinide—Pruritus—Imiquimod—skin cancer	0.000562	0.00525	CcSEcCtD
Nateglinide—SLC15A2—female reproductive system—skin cancer	0.000554	0.00851	CbGeAlD
Nateglinide—Nausea—Vemurafenib—skin cancer	0.000553	0.00517	CcSEcCtD
Nateglinide—Tremor—Temozolomide—skin cancer	0.000546	0.00511	CcSEcCtD
Nateglinide—Diarrhoea—Imiquimod—skin cancer	0.000543	0.00508	CcSEcCtD
Nateglinide—ABCC4—head—skin cancer	0.000536	0.00824	CbGeAlD
Nateglinide—PTGS1—connective tissue—skin cancer	0.000536	0.00824	CbGeAlD
Nateglinide—Dizziness—Imiquimod—skin cancer	0.000525	0.00491	CcSEcCtD
Nateglinide—Palpitations—Temozolomide—skin cancer	0.000515	0.00482	CcSEcCtD
Nateglinide—PTGS1—epithelium—skin cancer	0.000509	0.00782	CbGeAlD
Nateglinide—Cough—Temozolomide—skin cancer	0.000509	0.00476	CcSEcCtD
Nateglinide—Vomiting—Imiquimod—skin cancer	0.000505	0.00472	CcSEcCtD
Nateglinide—Rash—Imiquimod—skin cancer	0.000501	0.00468	CcSEcCtD
Nateglinide—Dermatitis—Imiquimod—skin cancer	0.0005	0.00468	CcSEcCtD
Nateglinide—SLC16A1—lymph node—skin cancer	0.000493	0.00758	CbGeAlD
Nateglinide—Neuropathy peripheral—Docetaxel—skin cancer	0.000486	0.00455	CcSEcCtD
Nateglinide—PTGS1—skin of body—skin cancer	0.000484	0.00744	CbGeAlD
Nateglinide—Jaundice—Docetaxel—skin cancer	0.000484	0.00452	CcSEcCtD
Nateglinide—Nausea—Imiquimod—skin cancer	0.000472	0.00441	CcSEcCtD
Nateglinide—Hepatobiliary disease—Docetaxel—skin cancer	0.000469	0.00439	CcSEcCtD
Nateglinide—SLC15A2—head—skin cancer	0.000463	0.00711	CbGeAlD
Nateglinide—Hyperhidrosis—Temozolomide—skin cancer	0.00046	0.0043	CcSEcCtD
Nateglinide—Fatigue—Dactinomycin—skin cancer	0.000454	0.00424	CcSEcCtD
Nateglinide—Urticaria—Bleomycin—skin cancer	0.000448	0.00419	CcSEcCtD
Nateglinide—ORM1—lymph node—skin cancer	0.000443	0.0068	CbGeAlD
Nateglinide—PTGS1—mammalian vulva—skin cancer	0.000441	0.00678	CbGeAlD
Nateglinide—Oedema peripheral—Docetaxel—skin cancer	0.000439	0.0041	CcSEcCtD
Nateglinide—Gastrointestinal pain—Dactinomycin—skin cancer	0.00043	0.00402	CcSEcCtD
Nateglinide—Erythema multiforme—Docetaxel—skin cancer	0.000421	0.00394	CcSEcCtD
Nateglinide—Dyspepsia—Temozolomide—skin cancer	0.000419	0.00392	CcSEcCtD
Nateglinide—Abdominal pain—Dactinomycin—skin cancer	0.000416	0.00389	CcSEcCtD
Nateglinide—Hypersensitivity—Bleomycin—skin cancer	0.000416	0.00389	CcSEcCtD
Nateglinide—CYP2C9—female reproductive system—skin cancer	0.000414	0.00636	CbGeAlD
Nateglinide—PPARG—lymph node—skin cancer	0.000414	0.00636	CbGeAlD
Nateglinide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000411	0.00384	CcSEcCtD
Nateglinide—Fatigue—Temozolomide—skin cancer	0.00041	0.00383	CcSEcCtD
Nateglinide—Asthenia—Bleomycin—skin cancer	0.000405	0.00378	CcSEcCtD
Nateglinide—Immune system disorder—Docetaxel—skin cancer	0.000402	0.00376	CcSEcCtD
Nateglinide—Pruritus—Bleomycin—skin cancer	0.000399	0.00373	CcSEcCtD
Nateglinide—Gastrointestinal pain—Temozolomide—skin cancer	0.000389	0.00364	CcSEcCtD
Nateglinide—ALB—lymph node—skin cancer	0.000388	0.00596	CbGeAlD
Nateglinide—Malnutrition—Docetaxel—skin cancer	0.000388	0.00362	CcSEcCtD
Nateglinide—Hypersensitivity—Dactinomycin—skin cancer	0.000388	0.00362	CcSEcCtD
Nateglinide—Dyspepsia—Fluorouracil—skin cancer	0.000386	0.00361	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000379	0.00354	CcSEcCtD
Nateglinide—PTGS1—female reproductive system—skin cancer	0.000378	0.00581	CbGeAlD
Nateglinide—Urticaria—Temozolomide—skin cancer	0.000378	0.00353	CcSEcCtD
Nateglinide—Asthenia—Dactinomycin—skin cancer	0.000377	0.00353	CcSEcCtD
Nateglinide—Abdominal pain—Temozolomide—skin cancer	0.000376	0.00352	CcSEcCtD
Nateglinide—ABCC4—lymph node—skin cancer	0.000376	0.00577	CbGeAlD
Nateglinide—Back pain—Docetaxel—skin cancer	0.000375	0.00351	CcSEcCtD
Nateglinide—Diarrhoea—Dactinomycin—skin cancer	0.00036	0.00336	CcSEcCtD
Nateglinide—Vomiting—Bleomycin—skin cancer	0.000359	0.00335	CcSEcCtD
Nateglinide—Rash—Bleomycin—skin cancer	0.000356	0.00332	CcSEcCtD
Nateglinide—Dermatitis—Bleomycin—skin cancer	0.000355	0.00332	CcSEcCtD
Nateglinide—Hypersensitivity—Temozolomide—skin cancer	0.000351	0.00328	CcSEcCtD
Nateglinide—Urticaria—Fluorouracil—skin cancer	0.000348	0.00326	CcSEcCtD
Nateglinide—Palpitations—Docetaxel—skin cancer	0.000343	0.0032	CcSEcCtD
Nateglinide—Asthenia—Temozolomide—skin cancer	0.000341	0.00319	CcSEcCtD
Nateglinide—Cough—Docetaxel—skin cancer	0.000338	0.00316	CcSEcCtD
Nateglinide—Pruritus—Temozolomide—skin cancer	0.000337	0.00315	CcSEcCtD
Nateglinide—Nausea—Bleomycin—skin cancer	0.000335	0.00313	CcSEcCtD
Nateglinide—Vomiting—Dactinomycin—skin cancer	0.000335	0.00313	CcSEcCtD
Nateglinide—Rash—Dactinomycin—skin cancer	0.000332	0.0031	CcSEcCtD
Nateglinide—Diarrhoea—Temozolomide—skin cancer	0.000326	0.00304	CcSEcCtD
Nateglinide—SLC15A2—lymph node—skin cancer	0.000324	0.00498	CbGeAlD
Nateglinide—Hypersensitivity—Fluorouracil—skin cancer	0.000323	0.00302	CcSEcCtD
Nateglinide—PTGS1—head—skin cancer	0.000316	0.00485	CbGeAlD
Nateglinide—CYP3A4—female reproductive system—skin cancer	0.000316	0.00485	CbGeAlD
Nateglinide—Dizziness—Temozolomide—skin cancer	0.000315	0.00294	CcSEcCtD
Nateglinide—Nausea—Dactinomycin—skin cancer	0.000312	0.00292	CcSEcCtD
Nateglinide—CYP2D6—female reproductive system—skin cancer	0.000311	0.00478	CbGeAlD
Nateglinide—Pruritus—Fluorouracil—skin cancer	0.00031	0.0029	CcSEcCtD
Nateglinide—Vomiting—Temozolomide—skin cancer	0.000303	0.00283	CcSEcCtD
Nateglinide—Rash—Temozolomide—skin cancer	0.0003	0.0028	CcSEcCtD
Nateglinide—Diarrhoea—Fluorouracil—skin cancer	0.0003	0.0028	CcSEcCtD
Nateglinide—Dermatitis—Temozolomide—skin cancer	0.0003	0.0028	CcSEcCtD
Nateglinide—Dizziness—Fluorouracil—skin cancer	0.00029	0.00271	CcSEcCtD
Nateglinide—Nausea—Temozolomide—skin cancer	0.000283	0.00264	CcSEcCtD
Nateglinide—Vomiting—Fluorouracil—skin cancer	0.000279	0.00261	CcSEcCtD
Nateglinide—Dyspepsia—Docetaxel—skin cancer	0.000279	0.0026	CcSEcCtD
Nateglinide—Rash—Fluorouracil—skin cancer	0.000276	0.00258	CcSEcCtD
Nateglinide—Dermatitis—Fluorouracil—skin cancer	0.000276	0.00258	CcSEcCtD
Nateglinide—Gastrointestinal disorder—Docetaxel—skin cancer	0.000273	0.00255	CcSEcCtD
Nateglinide—Fatigue—Docetaxel—skin cancer	0.000273	0.00255	CcSEcCtD
Nateglinide—Nausea—Fluorouracil—skin cancer	0.00026	0.00243	CcSEcCtD
Nateglinide—CYP2D6—head—skin cancer	0.00026	0.00399	CbGeAlD
Nateglinide—Gastrointestinal pain—Docetaxel—skin cancer	0.000259	0.00242	CcSEcCtD
Nateglinide—Abdominal pain—Docetaxel—skin cancer	0.00025	0.00234	CcSEcCtD
Nateglinide—Hypersensitivity—Docetaxel—skin cancer	0.000233	0.00218	CcSEcCtD
Nateglinide—Asthenia—Docetaxel—skin cancer	0.000227	0.00212	CcSEcCtD
Nateglinide—Pruritus—Docetaxel—skin cancer	0.000224	0.00209	CcSEcCtD
Nateglinide—PTGS1—lymph node—skin cancer	0.000221	0.0034	CbGeAlD
Nateglinide—Diarrhoea—Docetaxel—skin cancer	0.000217	0.00202	CcSEcCtD
Nateglinide—Dizziness—Docetaxel—skin cancer	0.000209	0.00196	CcSEcCtD
Nateglinide—Vomiting—Docetaxel—skin cancer	0.000201	0.00188	CcSEcCtD
Nateglinide—Rash—Docetaxel—skin cancer	0.0002	0.00187	CcSEcCtD
Nateglinide—Dermatitis—Docetaxel—skin cancer	0.000199	0.00186	CcSEcCtD
Nateglinide—Nausea—Docetaxel—skin cancer	0.000188	0.00176	CcSEcCtD
